# IQVIA Q3 2026 Earnings Beat

> IQVIA reports 8% revenue growth and 11.3% EPS rise as AI adoption accelerates client wins.
- Title: IQVIA Q3 2026 Earnings Beat · The Motley Fool | Shortify
- Summary: IQVIA reports 8% revenue growth and 11.3% EPS rise as AI adoption accelerates client wins. IQVIA exceeded earnings guidance with 8% revenue growth, 11.3% EPS…
- Keywords: iqvia, q3 2026, earnings, revenue, eps, client wins, commercial solutions, research and development, finance, money, 2026, Beat
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/27/iqvia-iqv-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-27T17:54:23+00:00
- Read time: 1 min
- Topics: iqvia, q3 2026, earnings, revenue, eps, ai, client wins, commercial solutions, research and development, finance, money
## Q3 2026 Results
IQVIA reported third quarter revenue of $4,428 million, 8% growth on reported basis.
## Organic Growth Acceleration
Organic revenue growth reached 6%, more than twofold the 2025 Q3 rate.
## Constant Currency Growth
Constant currency revenue growth at 8.6% despite foreign exchange fluctuations.
## Commercial Solutions Performance
Commercial Solutions revenue grew 6.9% to $1,789 million with strong full-service bookings.
## R&D Solutions Growth
R&D Solutions revenue grew 8.7% to $2,639 million with organic growth accelerating.
## Adjusted EBITDA Expansion
Adjusted EBITDA grew 8.7% to $1,032 million with 20 basis points margin expansion.
## Earnings Per Share
Adjusted diluted EPS rose 11.3% to $3.34, exceeding guidance.
## Book-to-Bill Ratio
Book-to-bill ratio at 1.2 reflecting strong full-service outsourcing awards.
## R&D Net New Bookings
R&D Solutions net new bookings reached $3.2 billion, 15% year-over-year increase.
## Backlog Adjustment
Contracted backlog adjusted to $32.6 billion after $2.1 billion removal of inactive trials.
## Emerging Biopharma Funding
Emerging biopharma funding reached $90 billion year to date, up 85% year over year.
## AI Agent Deployment
415 AI agents deployed to date, accelerating win rates by two to three points.
## Full-Year Guidance
Raised full-year revenue guidance to $17,350 million with 6.3% to 7% growth.
## Operational Margin Improvement
80 basis points of margin expansion from operational productivity programs.
## Pass-Through Impact
70 basis points headwind from pass-through revenues on gross margins.
## Q4 Financial Assumptions
Net interest expense of $210 million and weighted average shares of 169 million.
## Key takeaway

IQVIA exceeded earnings guidance with 8% revenue growth, 11.3% EPS increase, and strong AI-driven client wins in Q3 2026.